S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NYSE:DNA

Ginkgo Bioworks (DNA) Stock Price, News & Analysis

$1.16
+0.06 (+5.45%)
(As of 03/28/2024 ET)
Today's Range
$1.10
$1.20
50-Day Range
$1.05
$1.55
52-Week Range
$1.03
$2.55
Volume
26.13 million shs
Average Volume
24.64 million shs
Market Capitalization
$2.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.20

Ginkgo Bioworks MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
89.7% Upside
$2.20 Price Target
Short Interest
Bearish
19.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Ginkgo Bioworks in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$201,878 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.32) to ($0.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.38 out of 5 stars

Medical Sector

786th out of 939 stocks

Biological Products, Except Diagnostic Industry

130th out of 158 stocks

DNA stock logo

About Ginkgo Bioworks Stock (NYSE:DNA)

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

DNA Stock Price History

DNA Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Ginkgo Bioworks (NYSE:DNA) Trading Down 3.5%
DNA Apr 2024 0.500 call
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Is Ginkgo Bioworks Stock a Buy?
DNA May 2024 1.000 put
DNA Mar 2024 0.500 put
Ginkgo Bioworks: Multiple Red Flags
Ginkgo Bioworks: More Awful Revenue Guidance
CEO Dumps 20 Million Ginkgo Bioworks Shares
See More Headlines
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/29/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
1,218
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.20
High Stock Price Target
$3.00
Low Stock Price Target
$1.10
Potential Upside/Downside
+89.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-892,870,000.00
Net Margins
-355.08%
Pretax Margin
-355.11%

Debt

Sales & Book Value

Annual Sales
$251.46 million
Book Value
$0.55 per share

Miscellaneous

Outstanding Shares
2,152,400,000
Free Float
1,828,460,000
Market Cap
$2.50 billion
Optionable
Optionable
Beta
1.42
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

DNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings
or view top-rated stocks.

What is Ginkgo Bioworks' stock price target for 2024?

5 analysts have issued 12-month price objectives for Ginkgo Bioworks' stock. Their DNA share price targets range from $1.10 to $3.00. On average, they predict the company's stock price to reach $2.20 in the next year. This suggests a possible upside of 89.7% from the stock's current price.
View analysts price targets for DNA
or view top-rated stocks among Wall Street analysts.

How have DNA shares performed in 2024?

Ginkgo Bioworks' stock was trading at $1.69 at the beginning of the year. Since then, DNA shares have decreased by 31.4% and is now trading at $1.16.
View the best growth stocks for 2024 here
.

Are investors shorting Ginkgo Bioworks?

Ginkgo Bioworks saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 250,230,000 shares, an increase of 5.6% from the January 31st total of 236,910,000 shares. Based on an average daily volume of 21,150,000 shares, the days-to-cover ratio is currently 11.8 days. Approximately 19.0% of the company's stock are short sold.
View Ginkgo Bioworks' Short Interest
.

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our DNA earnings forecast
.

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) posted its quarterly earnings results on Thursday, February, 29th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The company earned $34.76 million during the quarter, compared to analysts' expectations of $40.37 million. Ginkgo Bioworks had a negative net margin of 355.08% and a negative trailing twelve-month return on equity of 48.23%. The firm's quarterly revenue was down 64.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.04) earnings per share.

What guidance has Ginkgo Bioworks issued on next quarter's earnings?

Ginkgo Bioworks updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $215.0 million-$235.0 million, compared to the consensus revenue estimate of $279.6 million.

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.15%), ARK Investment Management LLC (9.38%), Vanguard Group Inc. (6.27%), Vanguard Group Inc. (6.17%), Sumitomo Mitsui Trust Holdings Inc. (2.75%) and Nikko Asset Management Americas Inc. (2.75%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends
.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:DNA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners